IQVIA Holdings Inc.'s Q1 results highlighted strong profitability, robust TAS growth, and a healthy backlog, reaffirming its leadership in healthcare data and analytics. Despite sector headwinds, I remained bullish on IQVIA and expected Q2 to meet or beat estimates, viewing analyst forecasts as a conservative floor. The company did not disappoint. Key risks include delayed clinical trials, shri...
IQVIA Holdings Inc. (NYSE:IQV ) Q2 2025 Earnings Conference Call July 22, 2025 9:00 AM ET Company Participants Ari Bousbib - CEO & Chairman Kerri Joseph - Corporate Participant SVP of Investment Relation & Treasury - Corporate Participant Ronald E. Bruehlman - Executive VP & CFO Conference Call Participants Ann Kathleen Hynes - Mizuho Securities USA LLC, Research Division Christine Rains - Will...
Contract research firm IQVIA Holdings posted second-quarter profit and revenue above Wall Street expectations on Tuesday, as demand rose for its healthcare data and analytics services, sending shares up around 8% in premarket trading.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended June 30, 2025. Second-Quarter 2025 Operating Results Revenue for the second quarter of $4,017 millio...
I rate IQVIA as a hold due to long-term competitive threats, particularly from one player, and concerns about capital allocation and high debt. IQVIA's business model is solid, but declining gross margins, low ROIC, and slow innovation raise concerns about its ability to sustain long-term value. The competitor's more innovative, integrated ecosystem and better capital discipline position it to ...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its second-quarter 2025 financial results before the market opens on Tuesday, July 22, 2025. The IQVIA management team will also host a confe...
President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy. But will it work?
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.